Beta
Today
Capital & Financial MarketsMarkets & Customers 3 Nov 2026

Stevanato Group maintains 2026 guidance, flags slower 2027 growth on GLP-1 softness

Stevanato Group reported third-quarter 2026 revenue up 8% to EUR 326.1m and adjusted EBITDA up 14% to EUR 88.8m, with margin rising 150 basis points to 27.2%. The pharmaceutical packaging and drug-delivery group maintained its full-year 2026 guidance of EUR 1.260bn to EUR 1.280bn revenue, but said it now expects only low single-digit growth in 2027 as GLP-1 therapy volumes come in lower than previously anticipated.

Why this mattersLower GLP-1 volumes hit a drug class worth 17-18% of Stevanato's quarterly revenue; non-GLP-1 biologics, up more than 30% in the quarter, are carrying the offset.

  • Company expects low single-digit growth in 2027 as GLP-1 volumes and revenue come in below earlier expectations
  • Q3 2026 revenue rose 8% (8% organic) to EUR 326.1m
  • Adjusted EBITDA increased 14% to EUR 88.8m, margin up 150 basis points to 27.2%
  • Biopharmaceutical and Diagnostic Solutions revenue grew 11% organically to EUR 294.0m; Engineering segment revenue fell 12%
  • GLP-1 therapies represented about 17-18% of Q3 revenue; non-GLP-1 biologics grew more than 30%
  • Full-year 2026 guidance maintained: revenue EUR 1.260bn-1.280bn, adjusted EBITDA EUR 335.0m-345.2m
Stevanato Group
Sources ir.stevanatogroup.com
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-11-04 · Edited before publication: The Engineering segment's EUR 32.0m revenue is not in the excerpt and is removed. The why-it-matters line said injectable packaging growth in general is slowing, but the source reports non-GLP-1 biologics up more than 30%. Rewritten.
  • 2026-11-04 · Edited before publication: 'Show how concentrated injectable-packaging demand has become' is a claim about the whole sector that the source does not support. It is rewritten around Stevanato's own 17-18% GLP-1 exposure and the offset from non-GLP-1 biologics.